• Publications
  • Influence
Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.
TLDR
The recognition that contrast enhancement is nonspecific and may not always be a true surrogate of tumor response and the need to account for the nonenhancing component of the tumor mandate that new criteria be developed and validated to permit accurate assessment of the efficacy of novel therapies. Expand
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
TLDR
First-line use of bevacizumab did not improve overall survival in patients with newly diagnosed glioblastoma, and progression-free survival was prolonged but did not reach the prespecified improvement target. Expand
Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity.
TLDR
The data supporting MGMT as a major mechanism of chemotherapy resistance in malignant gliomas is reviewed and ongoing studies that are testing resistance-modulating strategies are described. Expand
Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups.
TLDR
The molecular classification proposed herein outperforms the current histopathological classification and thus might serve as a basis for the next World Health Organization classification of CNS tumors. Expand
Chemoradiotherapy in malignant glioma: standard of care and future directions.
TLDR
Although the relative contribution of the concomitant and the adjuvant chemotherapy, respectively, cannot be assessed, the early introduction of chemotherapy and the simultaneous administration with radiotherapy appear to be key for the improvement of outcome. Expand
Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma.
TLDR
In a cohort of patients with grade 2 glioma who were younger than 40 years of age and had undergone subtotal tumor resection or who were 40 yearsof age or older, progression-free survival and overall survival were longer among those who received combination chemotherapy in addition to radiation therapy than amongThose who received radiation therapy alone. Expand
Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial.
TLDR
This study did not demonstrate improved efficacy for DD temozolomide for newly diagnosed GBM, regardless of methylation status, but it did confirm the prognostic significance of MGMT methylation. Expand
Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma.
TLDR
EGFRvIII-targeted vaccination in patients with GBM warrants investigation in a phase III, randomized trial. Expand
Association and Interactions between DNA Repair Gene Polymorphisms and Adult Glioma
TLDR
Results suggest that polymorphisms in DNA repair genes may act individually or together to contribute to glioma risk. Expand
Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system.
TLDR
The Class I evidence of bevacizumab efficacy from the present study in the treatment of central nervous system radiation necrosis justifies consideration of this treatment option for people with radiation Necrosis secondary to the treatmentof head-and-neck cancer and brain cancer. Expand
...
1
2
3
4
5
...